Case Reports in Ophthalmology (Feb 2012)

Orbital Aspergillosis: Voriconazole – The New Standard Treatment

  • Derek H. Ohlstein,
  • Claudia Hooten,
  • Javier Perez,
  • Charles L. Clark III,
  • Hazem Samy

DOI
https://doi.org/10.1159/000336276
Journal volume & issue
Vol. 3, no. 1
pp. 46 – 53

Abstract

Read online

Background/Aim: To describe a case of invasive orbital aspergillosis and evaluate treatments and outcomes. Methods: A case report and review of orbital aspergillosis treatment with voriconazole in the English language literature. Conclusion: Amphotericin B with debridement is the current standard of care for orbital aspergillosis; however, its prognosis is unfavorable. When compared to amphotericin B, voriconazole demonstrates a survival benefit, has less systemic toxicity, and is better tolerated by patients. While a prospective trial comparing amphotericin B to voriconazole in orbital aspergillosis is not feasible, there is evidence to support the use of voriconazole as primary therapy.

Keywords